Darren Wijaya

Darren Wijaya

Auto-generated profile, based on publicly available information

Darren Wijaya

Department of Internal Medicine, Loma Linda University Health, Loma Linda, California, USA, lluh.org

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 September 2025 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
DWDarren Wijaya
Darren Wijaya
RBRiyan Bittar
Riyan Bittar
PSPranati Shah
Pranati Shah
FAFarris Al-Manaseer
Farris Al-Manaseer
AHAdam Hagele
Adam Hagele
MAMojtaba Akhtari
Mojtaba Akhtari
The COVID-19 pandemic led to the widespread adoption of cryopreserved peripheral blood stem cell (PBSC) grafts in allogeneic hematopoietic stem cell transplantation (HSCT), diverging from the traditional preference for fresh grafts. Although cryopreservation ensures graft availability during logistical disruptions, its impact on transplantation outcomes remains uncertain. Existing studies report mixed findings, and no consensus has been established regarding long-term outcomes. In the present study, we compared clinical outcomes of fresh versus cryopreserved allogeneic PBSC grafts in patients undergoing HSCT, with a focus on engraftment and survival outcomes, and evaluated the consistency of reported effects across studies, through a meta-analysis and systematic review of retrospective cohort studies published between 2005 and 2025. PubMed and Embase were searched through May 10, 2025. Primary outcomes included composite, primary, and secondary graft failure; secondary outcomes included engraftment times, overall survival (OS), and relapse-free survival (RFS). Random-effects and fixed-effects models were conducted using R, and Kaplan-Meier curves were digitized when necessary. Thirteen studies were included in the meta-analysis, and 19 studies were included in the systematic review. Fresh grafts were associated with significantly lower odds of composite graft failure (odds ratio [OR], 0.58), primary graft failure (OR, 0.60), and secondary graft failure (OR, 0.46), all with low heterogeneity. Neutrophil and platelet engraftment times were similar, although platelet engraftment showed a nonsignificant trend favoring fresh grafts (-1.34 days; P = .058). One-year and 2-year OS favored fresh grafts in fixed-effects models (OR, 1.15 and 1.16, respectively), but these associations were not significant under random-effects models owing to substantial heterogeneity. One-year RFS also favored fresh grafts in the fixed-effects model (OR, 1.25) but lost significance in the random-effects model. In contrast, 2-year RFS consistently favored fresh grafts across both models (OR, 1.21; 95% CI, 1.08 to 1.35; I² = 0%). Our findings indicate that fresh PBSC grafts are associated with significantly lower rates of graft failure and may confer long-term survival benefits compared to cryopreserved grafts. While survival outcomes varied by statistical model because of heterogeneity, no studies reported superior outcomes with cryopreserved products. These findings support the preferential use of fresh grafts when feasible. Preclinical and clinical studies are needed to further improve the cryopreservation process. Subgroup analyses also may help identify patient populations most likely to benefit from fresh grafts.

23 March 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
BJBowon Joung
Bowon Joung
EMEthan Miles
Ethan Miles
FAFarris Al-Manaseer
Farris Al-Manaseer
WJWon Jin Jeon
Won Jin Jeon
DWDarren Wijaya
Darren Wijaya
ECEsther Chong
Esther Chong
Background: Painful vaso-occlusive episodes (VOEs) are the hallmark of sickle cell disease (SCD) and account for frequent visits to the emergency department (ED) or urgent care (UC). Currently, the early administration of analgesics is recommended as initial management; however, there is a need for further understanding of the effect of prompt analgesics and hydration during VOEs. The objective of this study is to analyze the factors associated with the rate of hospital admission in the setting of time to intravenous (IV) analgesics and hydration. Method: This retrospective single-institution study reviewed adult and pediatric patients with SCD who presented with VOEs from January 2018 to August 2023. Results: Of 303 patient encounters, the rates of admission for the overall group, the subgroup which received IV hydration within 60 min of arrival, and the subgroup which received both IV analgesics and hydration within 60 min were 51.8%, 25.6% (RR = 0.46), and 18.2% (RR = 0.33), respectively. Further, factors such as gender and the use of hydroxyurea were found to be significantly associated with the rate of admission. Conclusions: This signifies the importance of standardizing the management of VOEs through the timely administration of IV analgesics and hydration in both adult and pediatric ED/UC.

1 January 2026 in Case Reports in Oncological Medicine
Verified
Journal Article
Open access
DWDarren Wijaya
Darren Wijaya
ZHZachary Hanson
Zachary Hanson
ELEric K. Lau
Eric K. Lau
MAMojtaba Akhtari
Mojtaba Akhtari
Scleromyxedema is a rare, chronic cutaneous mucinosis marked by widespread waxy papules and potential extracutaneous involvement. This case report discusses the management of a 48‐year‐old female diagnosed with scleromyxedema, who initially partially responded to high‐dose intravenous immunoglobulin (HDIVIG) therapy. After partial relapse, she was induced with bortezomib, a proteasome inhibitor, and dexamethasone, achieving significant clinical improvement. Long‐term maintenance with IVIG was utilized to prevent recurrence of symptoms. This case highlights the effectiveness of both HDIVIG and bortezomib–dexamethasone dual therapy as viable treatment options for scleromyxedema, emphasizing the importance of maintenance therapy to prevent relapse.